Frequency of Observed Side Effects of &quot;Sputnik V&quot; Vaccine in Vaccinated People in Ardabil Province , 2021

Mashahadi, Saeed; Habibzadeh, Shahram; Hamidkholgh, Gholamreza; Arabzadeh, Amirahmad; Safarzadeh, Elham

[Home ] [Archive]

[ فارسی ]

Journal of Ardabil University of Medical Sciences

Main Menu

Home

Journal Information

Editorial Board

Articles archive

For Authors

For Reviewers

Editorial Policy

Registration

Contact us

ISSN
2228-7280
eISSN
2228-7299

Indexing

Search in website

Receive site information

Creative commons

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

In Press

Back to the articles list

Back to browse issues page

Frequency of Observed Side Effects of "Sputnik V" Vaccine in Vaccinated People in Ardabil Province , 2021

Saeed Mashahadi

, Shahram Habibzadeh

, Gholamreza Hamidkholgh ^*

, Amirahmad Arabzadeh

, Elham Safarzadeh

Department of Emergency Medicine, Imam Khomeni hospital, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran , hamidkholgh@arums.ac.ir

Abstract: (46 Views)

Background: Severe acute respiratory syndrome coronavirus type 2 (SARS-COV2) caused more than one million deaths in the first 6 months of the pandemic and caused huge economic and social problems internationally. An effective vaccine is certainly essential to prevent further deaths. One of the vaccines used in the control and prevention of the disease was the Sputnik V vaccine, and in this study, the side effects of the Sputnik V vaccine in vaccinated individuals in Ardabil province were evaluated.
Methods: In this retrospective descriptive cross-sectional study, the side effects observed in individuals vaccinated with the "Sputnik V vaccine" in the first and second doses were examined. Demographic information such as age and gender, history of drug use, general side effects including respiratory, gastrointestinal and neurological side effects and local side effects such as pain, swelling, redness, muscle spasms, as well as the time of onset of side effects and the duration of side effects were recorded for all vaccinated individuals. After collection, the data were analyzed using statistical methods.
Results: Among general complications, body aches were the most common with 65.4% and palpitations were the least common with 1.71%. In terms of respiratory complications, sore throat and burning sensation in the throat were the most common with 8.3% and runny nose was the least common with 3.9%. Among gastrointestinal complications, nausea was the most common with 13.4% and vomiting was the least common with 2.0 %. In terms of local complications, injection site pain was the most common with 50.5% and armpit pain on the same side of the injection was the least common with 3.9%.
Conclusion: Side effects of the Sputnik V vaccine were usually mild to moderate and acceptable and tolerable.

Keywords: Side Effects, Sputnik V Vaccine, COVID-19

Full-Text [PDF 388 kb] (26 Downloads)

Type of Study: article | Subject: Internal diseases
Received: 2025/01/19 | Accepted: 2025/02/20

References

1. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. 2020;2(6):e286-e287.

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.

3. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R. World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet. 2020;396(10253):741-743.

4. Adedokun KA, Kamorudeen RT, Bello IO. Authorization of the first COVID-19 emergency vaccines: The matters arising. EXCLI J. 2021 Mar 15;20:655-660. doi: 10.17179/excli2021-3384.

5. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, Neels P. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022 May;21(5):609-619. doi: 10.1080/14760584.2022.2042257.

6. Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763-765.

7. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-632.

8. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642-643.

9. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.

10. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID‑19 vaccine safety. Int J Mol Med. 2020;46(5):1599-1602.

11. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897.

12. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-488.

13. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017;13(3):613-620.

14. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021;595(7867):339-340.

15. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. 2020;2(6):e286-e287.

16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.

17. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R. World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet. 2020;396(10253):741-743.

18. Adedokun KA, Kamorudeen RT, Bello IO. Authorization of the first COVID-19 emergency vaccines: The matters arising. EXCLI J. 2021 Mar 15;20:655-660. doi: 10.17179/excli2021-3384.

19. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, Neels P. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022 May;21(5):609-619. doi: 10.1080/14760584.2022.2042257.

20. Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763-765.

21. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-632.

22. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642-643.

23. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.

24. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID‑19 vaccine safety. Int J Mol Med. 2020;46(5):1599-1602.

25. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897.

26. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-488.

27. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017;13(3):613-620.

28. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021;595(7867):339-340.

Send email to the article author

Add your comments about this article